Sanofi Bids €308m To Buy Kiadis
Premium of 272%
Arthur Lahr, CEO of the Dutch biotech, said the offer is testimony to the uniqueness of the firm's natural killer (NK) cell platform "and the rapid success of Kiadis’s transformation."
You may also be interested in...
Sanofi’s decision is influenced by its own in-house options, but also by the growing competition in sickle cell gene therapy.
Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.
Sanofi R&D head John Reed says company has kept 95% of patients on its nearly 400 clinical trials and started 59 studies. Company has also stepped up collaborations and closed acquisitions, integrating employees remotely.